Format

Send to

Choose Destination
Gynecol Oncol. 2017 Sep;146(3):560-565. doi: 10.1016/j.ygyno.2017.07.006. Epub 2017 Jul 11.

Phase II trial of neoadjuvant chemotherapy followed by chemoradiation in locally advanced cervical cancer.

Author information

1
Instituto de Medicina Integral Prof. Fernando Figueira - IMIP, Recife, Brazil; Clínica Multihemo/Oncoclínicas do Brasil, Recife, Brazil. Electronic address: carla.rameri.de.azevedo@gmail.com.
2
Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil; Federal University of Rio de Janeiro State (UNIRIO), Rio de Janeiro -, Brazil.
3
Instituto de Medicina Integral Prof. Fernando Figueira - IMIP, Recife, Brazil; Faculdade Pernambucana de Saúde, Recife, Brazil.
4
Instituto de Medicina Integral Prof. Fernando Figueira - IMIP, Recife, Brazil.
5
D'or Institute for Research and Education (IDOR), Rio de Janeiro, Brazil.

Abstract

OBJECTIVE:

Cervical cancer is a global public health challenge. Since 1999, platin based chemoradiation (CRT) is the standard treatment for those patients with locally advanced disease. However, this population still has a dismal prognosis and, alternatives approaches such as adjuvant chemotherapy are controversial, especially because of increased toxicity. Neoadjuvant chemotherapy (NACT) could be an option for more intensive treatment with manageable toxicity.

METHODS:

A phase II, prospective, non-randomized trial was conducted at a reference center in Recife, Brazil. Locally advanced cervical cancer patients (Ib2-IVa) were treated with neoadjuvant cisplatin 35mg/m2 and gemcitabine 1000mg/m2 D1 and D8, for 2cycles. Then, they received CRT (50.4Gy) with weekly cisplatin 40mg/m2 followed by brachytherapy. Response rate (RR) and toxicity were the primary endpoints. Progression-free survival (PFS) and overall survival (OS) were secondary endpoints.

RESULTS:

Between Sep/2013 and Oct/2015, 50 patients were initiated on NACT and CRT. RR was 81% at the end of treatment. Hematological and gastrointestinal toxicity were most common. Grade 3/4 toxicity was 20% during NACT and 44% during CRT. Late adverse events were present in 20% of patients. PFS at 1 and 3-years were 73.4% (IC 58.7-83.6) and 53.9% (IC 36.9-68.3), respectively; and, OS at 1 and 3-years were 93.9% (IC 82.4-98.0) and 71.3% (IC 53.3-83.3), respectively.

CONCLUSION:

In our hands NACT in locally advanced cervical cancer patients did not show a meaningful improvement in ORR. Nevertheless, we believe it should be further explored in prospective trials.

KEYWORDS:

Cervical neoplasia; Chemotherapy; Clinical trial; Gemcitabine; Neoadjuvant therapy

PMID:
28709705
DOI:
10.1016/j.ygyno.2017.07.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center